First-line carboplatin-based chemotherapy may be beneficial for HER2-low advanced breast cancer: A retrospective analysis.

For patients with human epidermal growth factor receptor 2 (HER2)-low advanced breast cancer who had failed to meet with anthracycline or taxane, the application of HER2-targeted antibody-drug conjugates as second-line therapy could improve patients' outcomes, but it is unclear whether carboplatin-based first-line therapy will benefit these patients. This retrospective study was designed to explore whether carboplatin based first-line treatment could improve outcomes in HER2-low advanced breast cancer, and to analyze potential factors affecting efficacy and prognosis. 103 patients with HER2-negative metastatic breast cancer were treated with carboplatin based first-line therapy. The differences in progression-free survival (PFS), objective response rate (ORR), and adverse events were analyzed in different HER2 expression subgroups. The risk ratio (HR) and 95% confidence interval (CI) for PFS were estimated using Cox proportional risk models. The ORR for the whole group was 42.72% and the median PFS (mPFS) was 7.93 months (m). The ORR of HER2-low patients was significantly higher than HER2-zero patients (56.4% vs 27.1%, P = .003), and HER2-zero was an independent risk factor of ORR (OR 3.478, 95%CI 1.516-7.977, P = .003), especially in the HR-negative subgroup. The mPFS was significantly longer in patients with low neutrophil-to-lymphocyte ratio (NLR) scores than those with high NLR scores (P < .001). Multivariate analysis showed that young breast cancer (age < 40) (P = .006) and high NLR values (P = .001) were prognostic risk factors affecting mPFS. The main grade 3 to 4 adverse reactions were neutropenia (15.53%), anemia (15.53%), and leukopenia (11.65%). The first-line carboplatin-based chemotherapy is quite active and tolerable in patients with HER2-low advanced breast cancer, that higher response rates can be achieved. In cases where CDK4/6 inhibitors are inappropriate for use due to resistance to endocrine therapy or the urgent need for short-term clinical response, chemotherapy remains important. When it is necessary to consider the accessibility of antibody-drug conjugates and the economics of patients, carboplatin-based chemotherapy may be provided to HER2-low patients as a more convenient, cost-effective and efficient option on the front line. Forecasting the efficacy and prognosis via inflammatory index such as NLR before the commencement of the treatment could enhance the precision and efficiency of carboplatin-based regimens.